Company intelligence / Profile preview
AdvanCell
Sydney, New South Wales, Australiaadvancell.com.au ↗
- Ownership
- Private
- Employees
- ~60
- Development stage
- Other
01
Overview
AdvanCell's lead program, ADVC001, a Pb-212-based Targeted Alpha Therapy for metastatic prostate cancer, is currently enrolling patients in a multi-center Phase I/II dose escalation trial. The company has a deep pipeline of additional targeted alpha therapies at various stages of preclinical and early clinical development.[1][3][6]
- Therapeutic areas
- Oncology
- Modalities
- Targeted Alpha Therapies[212Pb]-based radiotherapeutics
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
Eli Lilly
Beyond the preview
Go deeper on AdvanCell.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AdvanCell.